Results 71 to 80 of about 2,657,498 (292)

Spontaneous Rupture of the Patellar and Contralateral Quadriceps Tendons Associated with Secondary Hyperparathyroidism in a Patient Receiving Long-term Dialysis

open access: yesJournal of the Formosan Medical Association, 2006
Although spontaneous rupture of the extensor tendon of the knee is more likely to occur in uremic patients with secondary hyperparathyroidism, simultaneous ruptures of bilateral knee extensor tendons is a rarely reported condition.
Chiu-Ming Chen   +2 more
doaj   +1 more source

Left parathyroid carcinoma with secondary hyperparathyroidism: a case report

open access: yesBMC Endocrine Disorders, 2023
Background Parathyroid carcinoma is a rare disease with a frequency of 0.005% of all malignancies [1, 2]. Various aspects of its pathogenesis, diagnosis, and treatment remain poorly understood.
Ko Yokoyama   +2 more
doaj   +1 more source

About A Rare Cause Of Primary Hyperparathyroidism [PDF]

open access: yes, 2011
Introduction: Primary hyperparathyroïdism is observed in 35 to 44 subjects/ 100000 persons. The increased production of parathyroid hormones is secondary to primary glandular modifications consisting mainly in adenomas.
Mona Mlika, Zidi-Moaffak Y , Lakhoua Y, Farah F, Kourda N, Ben Abdallah N, Zermani R, Baltagi-Ben Jilani S , Int J Cur Bio Med Sci.
core  

Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease

open access: yesScientific Reports, 2017
Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH)2D) levels, is commonly observed in patients with chronic
K. Kawakami   +7 more
semanticscholar   +1 more source

Prevalence of Secondary Hyperparathyroidism in Hemo- Dialysis Patients

open access: yesProceedings
Introduction: One persistent complication of chronic kidney disease is secondary hyperparathyroidism. Early diagnosis of this disease will reduce morbidity in patients undergoing hemodialysis.
Awais Amjad   +4 more
doaj   +1 more source

Brown mandibular tumour revealing secondary hyperparathyroidism: A case report and review of the literature

open access: yesAdvances in Oral and Maxillofacial Surgery, 2021
Introduction: The brown tumour is a benign lesion resulting from an anomaly of bone metabolism in the context of primary or secondary hyperparathyroidism.
Ulrich Opoko   +5 more
doaj  

Impaired Insulin sensitivity and Insulin secretion in Haemodialysis patients with and without Secondary Hyperparathyroidism [PDF]

open access: yes, 2004
The aim of our study was to investigate insulin sensitivity and beta cell function in hemodialysis (HD) patients without diabetes. We hypothesized that parathyroid gland function was a determinant of insulin sensitivity and/or beta cell function.
Gluvic, Zoran M.   +5 more
core  

The calcium-sensing receptor as a regulator of cellular fate in normal and pathological conditions [PDF]

open access: yes, 2013
The calcium-sensing receptor (CaSR) belongs to the evolutionarily conserved family of plasma membrane G protein-coupled receptors (GPCRs). Early studies identified an essential role for the CaSR in systemic calcium homeostasis through its ability to ...
Benoit, Yves   +3 more
core   +1 more source

Let-7 and MicroRNA-148 Regulate Parathyroid Hormone Levels in Secondary Hyperparathyroidism.

open access: yesJournal of the American Society of Nephrology, 2017
Secondary hyperparathyroidism commonly complicates CKD and associates with morbidity and mortality. We profiled microRNA (miRNA) in parathyroid glands from experimental hyperparathyroidism models and patients receiving dialysis and studied the function ...
V. Shilo   +6 more
semanticscholar   +1 more source

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B, P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may change in end‐stage renal disease (ESRD) patients with large inter‐individual variabilities (IIVs), leading to altered substrate drug exposure and ultimately elevated safety risk.
Weijie Kong   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy